ArticleInternal medicine (Tokyo, Japan)2026

Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 Insertion.

Yuichiro Yasuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.